The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to PPD Development LP with a potential value of $545,452,906 to provide comprehensive and rapid response capabilities for research programs through September 2028. Task orders issued against the contract include over $132 million for clinical trial management support services relating to COVID-19, as well as orders valued at $2.33 million, $2 million, and $82.5 million for research services supporting studies related to opioid use disorder, NIAID's research mission, and completion of the ACTIV-2 clinical trial, respectively. Places of performance include North Carolina, Maryland, and Washington, D.C.
The original solicitation sought proposals to establish an Indefinite Delivery Indefinite Quantity contract to support the National Institute of Allergy and Infectious Diseases' mission through a range of clinical, nonclinical and basic research services. This included areas such as clinical trials, manufacturing, animal studies, analytics, and storage to allow rapid and flexible responses to research needs and emerging disease threats domestically and abroad. The partial small business set aside supported tasks in areas like clinical research, vaccine development, and specialized services over a potential seven-year ordering period.
Generated 1/4/24, 10:30 PM